SCHEMBL23488147

SCHEMBL23488147

C=CCO[C@@H]1O[C@H](COC(=O)c2ccc(NC(=O)c3ccccc3)cc2)[C@@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.47
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
GAA P10253 1/20 0.47
SYNJ2 O15056 3/20 0.42
SLC22A1 O15245 1/20 0.41
PTPN1 P18031 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
TYMP P19971 1/20 0.41
MAOB P27338 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
XDH P47989 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28290744 0.86 SYNJ2 (0.42) SYNJ2SLC22A1TYMPMAOBXDH
SCHEMBL23488597 0.85 SMN1; SMN2 (0.55) SMN1; SMN2NPC1RAB9AGAASYNJ2
SCHEMBL21112979 0.84 MAOB (0.45) SMN1; SMN2SYNJ2SLC22A1ALDH1A1TYMP
SCHEMBL23488254 0.81 CHRNB2 (0.45) SYNJ2TYMPMAOBXDH
SCHEMBL23488247 0.81 RAB9A (0.57) SMN1; SMN2NPC1RAB9AGAASYNJ2
SCHEMBL21112930 0.80 TYMP (0.43) SYNJ2SLC22A1TYMPMAOBPOLB
SCHEMBL5604917 0.79 NPC1 (0.69) SMN1; SMN2NPC1RAB9AGAAPTPN1
SCHEMBL27464799 0.78 PTPN1 (0.47) PTPN1ALDH1A1MAOBPOLBMEN1
SCHEMBL16018720 0.78 LGALS3 (0.45) SYNJ2PTPN1ALDH1A1HTTTYMP
SCHEMBL19613824 0.76 PTPN1 (0.44) PTPN1ALDH1A1POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 SMN1; SMN2 3945/4885NPC1 1840/4885RAB9A 1043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.